Michael Richman - Jan 31, 2022 Form 4 Insider Report for NextCure, Inc. (NXTC)

Role
President & CEO, Director
Signature
/s/ Steven P. Cobourn, as attorney-in-fact for Michael Richman
Stock symbol
NXTC
Transactions as of
Jan 31, 2022
Transactions value $
$0
Form type
4
Date filed
2/2/2022, 03:18 PM
Previous filing
Jun 29, 2021
Next filing
Jun 24, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NXTC Employee Stock Option (Right to Buy) Award $0 +262K $0.00 262K Jan 31, 2022 Common Stock 262K $5.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth of the option vests on January 31, 2023. The remainder vests in 36 monthly installments beginning on February 28, 2023.